Migraine - FOI Response Register

We are seeking to understand the funding and delivery of Botox and anti-CGRP monoclonal antibody treatments (Ajovy, Aimovig, Emgality, Vyepti, Vydura & Aquipta) for migraine.  Could you please answer the following?

• Does the trust commission/fund Botox treatment for migraine (Y/N)?

I believe that the Botox branded Botulinum Toxin that we keep may be used in patients suffering from migraines.

• Does the trust commission/fund anti-CGRP treatments for migraine (Y/N)?

We do have some patients on these treatments but I am unable to link these with a specific indication.

• Does the trust actively provide Botox/anti-CGRP treatments for migraine as opposed to sending patients to another trust (Y/N)? In case the trust does not provide these treatments, please provide the name of the trust to which you refer migraine patients for these treatments?

 I believe that we use the Neurology service in NHS Grampian.

• In case the trust actively provides Botox/anti-CGRP treatments for migraine but does not commission/fund them, then please provide the name(s) of the other NHS organisations that commission/fund these treatments at your trust.

 Not applicable

1. How many patients have been treated with the following drugs in the past 4 months:

Atogepant (Aquipta) – any disease                 nil

Erenumab (Aimovig) - any disease                 5

Eptinezumab (Vyepti) – any disease  nil

Fremanezumab (Ajovy) - any disease            <5

Galcanezumab (Emgality) - any disease       nil

Rimegepant (Vydura) – any disease  nil

Where we have given <5 answers, in accordance with FOISA s 16(1), NHS Shetland confirms that it holds the information requested but that it is exempt from disclosure under FOISA s 38(1)(b) as read with s 38 (2A) as the information constitutes personal data and disclosure would breach the confidentiality of the data subjects.

• Botulinum Toxin (i.e., Botox, Dysport, Xeomin) - migraine ONLY       

      Unknown as a number of indications.